Bristol Myers Squibb’s Opdivo set for EMA approval in urothelial carcinoma

Bristol Myers Squibb (NYSE: BMY), a global leader in biopharmaceuticals, has reached a significant milestone with the Committee for Medicinal Products for Human Use (CHMP) ... Read More